Project supported by grants from the National Institutes of Health (U01DK62424) and Prostate SPORE (CA58204) to Ming-jer TSAT.
SRC-3/AIB1: transcriptional coactivator in oncogenesis1
Article first published online: 28 MAR 2006
Acta Pharmacologica Sinica
Volume 27, Issue 4, pages 387–394, April 2006
How to Cite
YAN, J., TSAI, S. Y. and TSAI, M.-j. (2006), SRC-3/AIB1: transcriptional coactivator in oncogenesis. Acta Pharmacologica Sinica, 27: 387–394. doi: 10.1111/j.1745-7254.2006.00315.x
- Issue published online: 28 MAR 2006
- Article first published online: 28 MAR 2006
- Received 2005-12-12 Accepted 2006-01-17
- mouse model;
- signal transduction
Steroid receptor coactivator-3 (SRC-3, also known as NCoA3, AIB1, p/CIP, RAC3, ACTR, and TRAM1), localized on a frequently amplified region, 20q12, has been associated with multiple cancers, including breast, gastric and prostate cancers. Although SRC-3 has been implicated as an oncogene, compelling evidence has only recently emerged implicating it as a causal factor in the genesis of human cancers. Here, we summarize recent evidence that indicates aberrant SRC-3 expression is important in hormone-sensitive and -insensitive human cancers.